Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

Overview of attention for article published in JAMA Neurology, March 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 5,925)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 291 news stories from 241 outlets.

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with…

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with…

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with…

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 287 additional news stories.